Physician profile
Corrine Smith
NPI 1992476923
$5,704.84
in general payments reported to CMS, 2019-2025
34 companies · $953 in 2025
The $953 reported for 2025 was more than what 84% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $111 · 2022: $36.35 · 2023: $3,258 · 2024: $1,347 · 2025: $953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,534 · Travel and Lodging: $857 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,533.72 |
| Travel and Lodging | $856.76 |
| Education | $167.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,112.74 | 2023-2025 | Fasenra, Airsupra, Tezspire |
| Intuitive Surgical, INC. | $905.71 | 2023 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $567.93 | 2023-2024 | Nucala, Arexvy, Shingrix |
| Regeneron Healthcare Solutions, INC. | $477.23 | 2023-2024 | Dupixent |
| Grifols USA, LLC | $273.69 | 2023-2024 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $265.70 | 2023-2024 | Yupelri, Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.70 | 2023-2024 | Ofev, Jardiance |
| Daiichi Sankyo INC. | $213.32 | 2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $189.40 | 2024-2025 | Keytruda, Verquvo, Lynparza |
| United Therapeutics Corporation | $177.60 | 2023-2024 | Tyvaso |
| Insmed, INC. | $116.56 | 2023-2024 | Arikayce |
| Novo Nordisk INC | $110.88 | 2021 | |
| Janssen Pharmaceuticals, INC | $108.45 | 2023-2024 | Xarelto |
| Abbvie INC. | $98.54 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $84.19 | 2025 | Opdivo, Opdualag |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $78.29 | 2023 | Acthar |
| Actelion Pharmaceuticals US, INC. | $71.43 | 2023-2024 | Opsumit, Uptravi |
| Gilead Sciences, INC. | $67.28 | 2025 | Trodelvy |
| Jazz Pharmaceuticals INC. | $62.00 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.96 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $54.45 | 2024 | |
| Amgen INC. | $46.63 | 2023-2024 | Tezspire |
| Novartis Pharmaceuticals Corporation | $45.41 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $42.72 | 2024 | Arcalyst |
| Janssen Biotech, INC. | $39.75 | 2025 | Rybrevant |
| Lilly USA, LLC | $36.35 | 2022 | |
| Eisai INC. | $28.68 | 2025 | |
| Celgene Corporation | $26.64 | 2025 | Opdualag |
| Genzyme Corporation | $23.88 | 2024 | |
| Inspire Medical Systems, INC. | $19.17 | 2023 | Inspire |
| Puma Biotechnology, INC. | $18.56 | 2025 | |
| Adc Therapeutics America, INC. | $17.96 | 2025 | |
| Array Biopharma INC | $17.18 | 2025 | Braftovi, Lorbrena, Mektovi |
| Kyowa Kirin, INC. | $15.86 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corrine Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.